Tarsus Pharmaceuticals, Inc. TARS Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported finite-lived intangible assets - expected amortization expense (year one) of $961K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one) decreased by 0.0% year-over-year, from $961K to $961K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one)?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one) has grown at a 55.0% compound annual growth rate (CAGR), from $400K to $961K.
- What does finite-lived intangible assets - expected amortization expense (year one) mean?
- This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.